MicroPort has its headquarters in ZJ Hi-Tech Park, Shanghai and production and research centers in Shanghai, Suzhou, Jiaxing, Dongguan, Memphis (USA), Clamart (France), Saluggia (Italy) and Santo Domingo (Dominican Republic). Subsidiaries of Microport include MicroPort Othopedics, MicroPOrt CRM, Suzhou Microport Orthopedics Scientific, Shanghai MicroPort Endovascular MedTech, Shanghai MicroPort EP MedTech, MicroPort NeuroTech (Shanghai), Shanghai MicroPort CardioFlow Medtech, MicroPort Soaring CRM (Shanghai), Shanghai MicroPort Lifesciences, Shanghai Microport Access Medtech, Dongguan Kewei Medical Instrument, MicroPort (Shanghai) Medbot and MicroPort Rehab Technologies.
MicroPort’s membrane oxygenation system or KW membrane oxygenator is used to add oxygen to and remove carbon dioxide from blood to imitate lung function in cardiopulmonary bypass an to oxygenate blood in longer term life support called extracorporeal membrane oxygenation (EMO), a medical intervention used in critical care patients such as severe lung damage from infection or shock after a massive heart attack. EMO may be used in the critical care of patients with severe forms of COVID-19.
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.